Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 993

1.

Comprehensive Review of Molecular Mechanisms during Cholestatic Liver Injury and Cholangiocarcinoma.

Virani S, Akers A, Stephenson K, Smith S, Kennedy L, Alpini G, Francis H.

J Liver. 2018;7(3). pii: 231. doi: 10.4172/2167-0889.1000231. Epub 2018 Sep 20.

2.

Clinical practice guidelines for IgG4-related sclerosing cholangitis.

Kamisawa T, Nakazawa T, Tazuma S, Zen Y, Tanaka A, Ohara H, Muraki T, Inui K, Inoue D, Nishino T, Naitoh I, Itoi T, Notohara K, Kanno A, Kubota K, Hirano K, Isayama H, Shimizu K, Tsuyuguchi T, Shimosegawa T, Kawa S, Chiba T, Okazaki K, Takikawa H, Kimura W, Unno T, Yoshida M.

J Hepatobiliary Pancreat Sci. 2018 Dec 21. doi: 10.1002/jhbp.596. [Epub ahead of print]

PMID:
30575336
3.

Platelet-Derived Growth Factor-D Enables Liver Myofibroblasts to Promote Tumor Lymphangiogenesis in Cholangiocarcinoma.

Cadamuro M, Brivio S, Mertens J, Vismara M, Moncsek A, Milani C, Fingas C, Cristina Malerba M, Nardo G, Dall'Olmo L, Milani E, Mariotti V, Stecca T, Massani M, Spirli C, Fiorotto R, Indraccolo S, Strazzabosco M, Fabris L.

J Hepatol. 2018 Dec 13. pii: S0168-8278(18)32620-5. doi: 10.1016/j.jhep.2018.12.004. [Epub ahead of print]

PMID:
30553841
4.

Rare case of idiopathic sclerosing cholangitis, which was difficult to distinguish from cholangiocarcinoma: A case report.

Shichi S, Einama T, Suzuki M, Matsui H, Kanazawa R, Shibuya K, Suzuki T, Matsuzawa F, Nakachi K, Hashimoto T, Kondo N, Abe H, Taketomi A.

Exp Ther Med. 2018 Dec;16(6):5224-5226. doi: 10.3892/etm.2018.6832. Epub 2018 Oct 5.

5.

Fibroinflammatory Liver Injuries as Preneoplastic Condition in Cholangiopathies.

Cannito S, Milani C, Cappon A, Parola M, Strazzabosco M, Cadamuro M.

Int J Mol Sci. 2018 Dec 4;19(12). pii: E3875. doi: 10.3390/ijms19123875. Review.

6.

Diagnostic performance of a stepwise cytological algorithm for biliary malignancy in primary sclerosing cholangitis.

von Seth E, Ouchterlony H, Dobra K, Hjerpe A, Arnelo U, Haas S, Bergquist A.

Liver Int. 2018 Dec 2. doi: 10.1111/liv.14007. [Epub ahead of print]

PMID:
30507030
7.

Statin Use is Associated with Improved Outcomes of Patients With Primary Sclerosing Cholangitis.

Stokkeland K, Höijer J, Bottai M, Söderberg-Löfdal K, Bergquist A.

Clin Gastroenterol Hepatol. 2018 Nov 15. pii: S1542-3565(18)31245-X. doi: 10.1016/j.cgh.2018.11.002. [Epub ahead of print]

PMID:
30448601
8.

Metal, magnet or transplant: options in primary sclerosing cholangitis with stricture.

Ahmad J.

Hepatol Int. 2018 Nov;12(6):510-519. doi: 10.1007/s12072-018-9906-6. Epub 2018 Nov 14. Review.

PMID:
30430358
9.
10.

False negative and false positive rates in common bile duct brushing cytology, a single center experience.

Geramizadeh B, Moughali M, Shahim-Aein A, Memari S, Ghetmiri Z, Taghavi A, Bagheri Lankarani K.

Gastroenterol Hepatol Bed Bench. 2018 Fall;11(4):296-300.

11.

Gamma Glutamyltransferase Reduction Is Associated With Favorable Outcomes in Pediatric Primary Sclerosing Cholangitis.

Deneau MR, Mack C, Abdou R, Amin M, Amir A, Auth M, Bazerbachi F, Marie Broderick A, Chan A, DiGuglielmo M, El-Matary W, El-Youssef M, Ferrari F, Furuya KN, Gottrand F, Gupta N, Homan M, Jensen MK, Kamath BM, Mo Kim K, Kolho KL, Konidari A, Koot B, Iorio R, Martinez M, Mohan P, Palle S, Papadopoulou A, Ricciuto A, Saubermann L, Sathya P, Shteyer E, Smolka V, Tanaka A, Valentino PL, Varier R, Venkat V, Vitola B, Vos MB, Woynarowski M, Yap J, Miloh T.

Hepatol Commun. 2018 Sep 25;2(11):1369-1378. doi: 10.1002/hep4.1251. eCollection 2018 Nov.

12.

Individual probe based confocal laser endomicroscopy criteria in the analysis of indeterminate biliary strictures.

Dubow M, Tatman PD, Shah RJ.

Scand J Gastroenterol. 2018 Nov 5:1-6. doi: 10.1080/00365521.2018.1512151. [Epub ahead of print]

PMID:
30394137
13.

Role of TGR5 (GPBAR1) in Liver Disease.

Keitel V, Häussinger D.

Semin Liver Dis. 2018 Nov;38(4):333-339. doi: 10.1055/s-0038-1669940. Epub 2018 Oct 24.

PMID:
30357770
14.

Serum metabolites as diagnostic biomarkers for cholangiocarcinoma, hepatocellular carcinoma and primary sclerosing cholangitis.

Banales JM, Iñarrairaegui M, Arbelaiz A, Milkiewicz P, Muntane J, Muñoz-Bellvis L, La Casta A, Gonzalez LM, Arretxe E, Alonso C, Martínez-Arranz I, Lapitz A, Santos-Laso A, Avila MA, Martínez-Chantar ML, Bujanda L, Marin JJG, Sangro B, Macias RIR.

Hepatology. 2018 Oct 16. doi: 10.1002/hep.30319. [Epub ahead of print]

PMID:
30325540
15.

Risk factors for extrahepatic cholangiocarcinoma: a case-control study in China.

Zhou Z, Nie SD, Jiang B, Wang J, Lv P.

Eur J Cancer Prev. 2018 Oct 5. doi: 10.1097/CEJ.0000000000000468. [Epub ahead of print]

PMID:
30299315
16.

Recent developments in the research on biomarkers of cholangiocarcinoma in primary sclerosing cholangitis.

Wannhoff A, Gotthardt DN.

Clin Res Hepatol Gastroenterol. 2018 Sep 25. pii: S2210-7401(18)30177-3. doi: 10.1016/j.clinre.2018.08.013. [Epub ahead of print] Review.

PMID:
30266579
17.

Mucosal Autoimmunity to Cell-Bound GP2 Isoforms Is a Sensitive Marker in PSC and Associated With the Clinical Phenotype.

Sowa M, Kolenda R, Baumgart DC, Pratschke J, Papp M, Tornai T, Suchanski J, Bogdanos DP, Mytilinaiou MG, Hammermann J, Laass MW, Conrad K, Schramm C, Franke A, Roggenbuck D, Schierack P.

Front Immunol. 2018 Aug 28;9:1959. doi: 10.3389/fimmu.2018.01959. eCollection 2018.

18.

IgG4-Related Sclerosing Cholangitis and Primary Sclerosing Cholangitis.

Tanaka A.

Gut Liver. 2018 Sep 13. doi: 10.5009/gnl18085. [Epub ahead of print] Review.

19.

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei in a liver-transplanted patient: a case report.

Thorgersen EB, Melum E, Folseraas T, Larsen SG, Line PD.

World J Surg Oncol. 2018 Sep 5;16(1):180. doi: 10.1186/s12957-018-1482-7.

20.

Primary Sclerosing Cholangitis, Part 2: Cancer Risk, Prevention, and Surveillance.

Tabibian JH, Ali AH, Lindor KD.

Gastroenterol Hepatol (N Y). 2018 Jul;14(7):427-432.

Supplemental Content

Loading ...
Support Center